Investors

Investor Relations

Landing - Corporate Profile Text

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

News Releases

September 15, 2021
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
Clinical collaboration to assess HB-200 in combination with KEYTRUDA ® (pembrolizumab) as first-line treatment HOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022 NEW YORK and VIENNA, Austria, Sept. 15, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc.
September 7, 2021
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the